Artivion insider converts options and reduces holding to 172,129 shares

Rhea-AI Filing Summary

Jean F. Holloway, SVP and General Counsel of Artivion, Inc. (AORT), reported securities transactions dated 08/12/2025. She exercised stock options covering 16,975 underlying shares with a conversion/exercise price of $26.24 (option grant dated 02/19/2021, vesting 33 1/3% per year and first exercisable on 02/19/2021). On the same date she sold 16,975 shares at a weighted-average price of about $43.011 and an additional 6,381 shares at about $43.018. The filings show her beneficial ownership moved from 195,485 shares to 178,510 and then to 172,129 shares following the reported transactions. Footnotes disclose the weighted-average sale price ranges and offer to provide per-price details on request.

Positive

• Exercised vested options converting 16,975 option shares into common stock at a conversion price of $26.24.
• Disclosure includes vesting and expiration details (grant date 02/19/2021, vesting 33 1/3% annually, expiration 02/19/2027) and weighted-average sale price ranges.

Negative

• Insider sold 23,356 shares on 08/12/2025 (16,975 and 6,381 shares) at weighted-average prices of about $43.011 and $43.018, reducing beneficial ownership to 172,129 shares.
• Substantial same-day disposition of shares acquired by exercise is reported, lowering the reporting person's holdings.

Insights

Securities Analyst

TL;DR: Insider exercised vested options then executed same-day sales, netting proceeds while reducing holdings to 172,129 shares.

The Form 4 documents an exercise of options for 16,975 shares at a $26.24 conversion price and contemporaneous sales totaling 23,356 shares at weighted-average prices around $43.01 on 08/12/2025. The filings provide sequential beneficial-ownership counts that fall to 172,129 shares after the transactions. The disclosure includes weighted-average price ranges for the sales, with an offer to provide per-price detail on request. From a market-impact perspective the filing is a clear, routine insider reporting of option exercise and share disposition.

Corporate Governance Expert

TL;DR: Form 4 shows compliant insider disclosure of option exercise, vesting terms, and subsequent sales; no additional governance exceptions noted.

The report identifies Holloway as an officer (SVP, General Counsel) and supplies option vesting information (33 1/3% annually, grant date 02/19/2021) and option expiration date (02/19/2027). The filing is signed and includes explanatory footnotes about weighted-average sale prices and ranges. The form does not assert other arrangements in the visible text. This appears to be standard Section 16 reporting rather than a governance event.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Holloway Jean F

(Last) (First) (Middle)

1655 ROBERTS BLVD., NW

(Street)

KENNESAW GA 30144

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ARTIVION, INC. [ AORT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/12/2025		M		16,975	A	$26.24	195,485	D
Common Stock	08/12/2025		S		16,975	D	$43.011(1)	178,510	D
Common Stock	08/12/2025		S		6,381	D	$43.018(2)	172,129	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option(Right to Buy)	$26.24	08/12/2025		M			16,975	02/19/2021(3)	02/19/2027	Common Stock	16,975	$0	0	D

Explanation of Responses:

1. Reflects weighted average price. Range of prices were between $42.14 to $43.65. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

2. Reflects weighted average price. Range of prices were between $42.12 to $43.62. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

3. Stock option vests 33 1/3% per year beginning on the first anniversary of the grant date. The first exercisable date was February 19, 2021.

Remarks:

	/s/ Jean F Holloway	08/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Jean F. Holloway report on the AORT Form 4?

The filing reports an 08/12/2025 exercise of 16,975 option shares at $26.24 and sales of 16,975 shares at a weighted-average of $43.011 and 6,381 shares at a weighted-average of $43.018.

How did Holloway's beneficial ownership change after the transactions?

Beneficial ownership was reported as 195,485 shares, then 178,510, and finally 172,129 shares following the reported transactions.

What are the option vesting and expiration details disclosed?

The option grant date is 02/19/2021, vests 33 1/3% per year beginning on the first anniversary, first exercisable on 02/19/2021, and expires on 02/19/2027.

Were the sale prices reported as exact or weighted averages?

The filing reports weighted-average sale prices (~$43.011 and ~$43.018) and footnotes state price ranges for the transactions with an offer to provide per-price details on request.

Does the Form 4 indicate the transactions were part of a 10b5-1 trading plan?

The visible filing does not indicate that a 10b5-1 plan was checked or asserted for these transactions in the provided text.